ANTI‐TUMOR ACTIVITY OF DARATUMUMAB, A NOVEL HUMAN ANTI CD38 MONOCLONAL ANTIBODY, IN IN VITRO AND IN VIVO MODELS OF B‐CELL NON‐HODGKIN LYMPHOMA. (June 2017)